drugset / Trial / NCT01251367

Dysport® Adult Lower Limb Spasticity Follow-on Study

NCT01251367 ↗

Phase 3 Completed 352 enrolled Ipsen
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with lower limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.

Timeline

Start
2011-06
Primary completion
2015-04
Completion
2015-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 1000 iu Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 1500 iu Intramuscular